Ondansetron Syri Pharma (Ondansetron)

Ondansetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting across several clinical pathways.

• Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes.
• Radiotherapy‑induced nausea and vomiting: helps control nausea during and after radiation treatment.
• Post‑operative nausea and vomiting: lowers the incidence of nausea and vomiting after surgical procedures.
• Pregnancy‑associated nausea (hyperemesis gravidarum): provides symptomatic relief when other measures are insufficient.

• Ondansetron blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By preventing serotonin from binding to these receptors, it interrupts the neural signalling cascade that initiates the vomiting reflex, thereby reducing nausea and vomiting.

Adverse reactions to ondansetron are generally dose‑related and may vary in frequency.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: reduced bowel motility.
• Diarrhoea: occasional loose stools.
• Fatigue: feeling of tiredness or reduced energy.
• Dizziness: transient light‑headedness.
• Injection site pain (if administered parenterally).

Serious or Rare Side Effects

• Cardiac arrhythmia: QT‑interval prolongation, especially with rapid IV administration.
• Severe hypersensitivity: rash, pruritus, angio‑oedema or anaphylaxis.
• Serotonin syndrome: rare when combined with other serotonergic agents.
• Hepatic dysfunction: elevated liver enzymes.
• Severe constipation or paralytic ileus.
• Neuro‑muscular weakness: rare neuromuscular complications.

When prescribing ondansetron, clinicians should consider patient‑specific factors and monitor for known safety concerns.

• Cardiac monitoring: assess baseline ECG in patients with known cardiac disease or electrolyte abnormalities.
• Concomitant serotonergic drugs: avoid or use with caution to reduce serotonin syndrome risk.
• Electrolyte imbalance: correct hypokalaemia or hypomagnesaemia before initiation.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Renal or hepatic impairment: dose adjustment may be required based on clinical judgement.
• Store at below 25 °C: keep in the original container, protect from moisture and light.

Ondansetron may interact with several medication classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Apomorphine: concurrent use can cause profound hypotension and loss of consciousness.
• Certain anti‑arrhythmic agents (e.g., quinidine, amiodarone): may increase QT‑interval prolongation risk.

Moderate Interactions (Monitor Closely)

• Other serotonergic agents (SSRIs, SNRIs, tramadol, linezolid): monitor for signs of serotonin syndrome.
• CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): modestly increase exposure.
• Diuretics causing electrolyte loss: monitor electrolytes to reduce arrhythmia risk.